Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 4.67 AUD 1.74% Market Closed
Market Cap: 379.4m AUD
Have any thoughts about
Mayne Pharma Group Ltd?
Write Note
MYX
/
Cash Flow Statement
/
Other

Mayne Pharma Group Ltd
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mayne Pharma Group Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Mayne Pharma Group Ltd
ASX:MYX
Other
AU$5.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Other
-AU$561.4k
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Other
-AU$20k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
32%
Botanix Pharmaceuticals Ltd
ASX:BOT
Other
-AU$5.8m
CAGR 3-Years
N/A
CAGR 5-Years
-193%
CAGR 10-Years
-37%
Probiotec Ltd
ASX:PBP
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arovella Therapeutics Ltd
ASX:ALA
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayne Pharma Group Ltd
Glance View

Market Cap
379.4m AUD
Industry
Pharmaceuticals

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

MYX Intrinsic Value
8.02 AUD
Undervaluation 42%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Mayne Pharma Group Ltd's Other?
Other
5.7m AUD

Based on the financial report for Jun 30, 2024, Mayne Pharma Group Ltd's Other amounts to 5.7m AUD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.